Ignite Creation Date:
2025-12-24 @ 5:06 PM
Ignite Modification Date:
2025-12-28 @ 7:01 PM
Study NCT ID:
NCT06136650
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2023-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-18
Start Date Type:
ACTUAL
Primary Completion Date:
2028-05-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-12-02
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-13
First Submit QC Date:
None
Study First Post Date:
2023-11-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED